<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Kolarova TR</submitter><funding>National Center for Advancing Translational Sciences</funding><funding>NCATS NIH HHS</funding><funding>NHLBI Division of Intramural Research</funding><funding>NHLBI NIH HHS</funding><funding>NIGMS NIH HHS</funding><pagination>456-458</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10922755</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>143(3)</volume><pubmed_abstract>Uterine leiomyomas may affect the performance of cell-free DNA (cfDNA)-based noninvasive prenatal testing (NIPT). We conducted a retrospective cohort study of pregnant individuals with and without leiomyomas undergoing first-trimester cfDNA-based NIPT. Characteristics of NIPT in patients with leiomyomas (n=122) were compared with those in patients without leiomyomas (n=937). Mean fetal fraction was lower in patients with leiomyomas compared with patients without (10.0% vs 11.5%; P =.001); however, the rate of indeterminate results was different only in patients without obesity (body mass index [BMI] lower than 30) (5.3% vs 1.5%; P =0.03). Total cfDNA concentration was higher in patients with leiomyomas ( P =.002), suggesting possible dilution of the fetal fraction. Leiomyoma size did not affect NIPT metrics. In conclusion, uterine leiomyomas are associated with lower fetal fraction and, in patients without obesity, with a higher rate of indeterminate results independent of leiomyoma size.</pubmed_abstract><journal>Obstetrics and gynecology</journal><pubmed_title>Effect of Uterine Leiomyomas on Noninvasive Prenatal Testing Parameters in the First Trimester.</pubmed_title><pmcid>PMC10922755</pmcid><funding_grant_id>K08 HL150169</funding_grant_id><funding_grant_id>K08HL150169</funding_grant_id><funding_grant_id>T32 GM007454</funding_grant_id><funding_grant_id>UL1 TR002319</funding_grant_id><pubmed_authors>Buchan JG</pubmed_authors><pubmed_authors>Lockwood C</pubmed_authors><pubmed_authors>MacKinnon H</pubmed_authors><pubmed_authors>Chen L</pubmed_authors><pubmed_authors>Kolarova TR</pubmed_authors><pubmed_authors>Shree R</pubmed_authors><pubmed_authors>Alderson A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Effect of Uterine Leiomyomas on Noninvasive Prenatal Testing Parameters in the First Trimester.</name><description>Uterine leiomyomas may affect the performance of cell-free DNA (cfDNA)-based noninvasive prenatal testing (NIPT). We conducted a retrospective cohort study of pregnant individuals with and without leiomyomas undergoing first-trimester cfDNA-based NIPT. Characteristics of NIPT in patients with leiomyomas (n=122) were compared with those in patients without leiomyomas (n=937). Mean fetal fraction was lower in patients with leiomyomas compared with patients without (10.0% vs 11.5%; P =.001); however, the rate of indeterminate results was different only in patients without obesity (body mass index [BMI] lower than 30) (5.3% vs 1.5%; P =0.03). Total cfDNA concentration was higher in patients with leiomyomas ( P =.002), suggesting possible dilution of the fetal fraction. Leiomyoma size did not affect NIPT metrics. In conclusion, uterine leiomyomas are associated with lower fetal fraction and, in patients without obesity, with a higher rate of indeterminate results independent of leiomyoma size.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Mar</publication><modification>2025-04-04T19:26:25.538Z</modification><creation>2025-04-04T19:26:25.538Z</creation></dates><accession>S-EPMC10922755</accession><cross_references><pubmed>38207338</pubmed><doi>10.1097/aog.0000000000005504</doi><doi>10.1097/AOG.0000000000005504</doi></cross_references></HashMap>